350 rub
Journal №6 for 2013 г.
Article in number:
New approaches to anticancer drug design
Keywords: antitumor drugs gene therapy
Authors:
S.A. Kondratyeva
Abstract:
Main research directions of anticancer drugs investigations are considered, including the increase of the drugs specificity and solving the problem of their targeted delivery.
Pages: 27-29
References
  1. ChenJ. etal.A restricted cell population propagates glioblastoma growth after chemotherapy // Nature. 2012. V. 488. № 7412. P. 522-526.
  2. Driessens G. et al. Defining the mode of tumour growth by clonal analysis // Nature. 2012.
  3. Schepers A.G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas // Science Signaling. 2012. V. 337. № 6095. P. 730.
  4. Thiery J.P. et al. Epithelial-mesenchymal transitions in development and disease // Cell. 2009. V. 139. № 5. P. 871-890.
  5. Clayton S., Mousa S.A. Therapeutics formulated to target cancer stem cells: Is it in our future - // Cancer cell international. 2011. V. 11. № 1. P. 7.
  6. Grotenhuis B.A. et al. Preoperative Assessment of Tumor Location and Station-Specific Lymph Node Status in Patients with Adenocarcinoma of the Gastroesophageal Junction // World journal of surgery. 2013. V. 37. № 1. P. 147-155.
  7. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities // Cell Stem Cell. 2012. V. 10. № 6. P. 717-728.
  8. Severin E., Rodina A. Problemy' i perspektivy' sovremennoj protivoopuxolevoj terapii // Uspexi biologicheskoj ximii. 2006. № 46. P. 43-64.
  9. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential // International journal of nanomedicine. 2006. V. 1. № 3. P. 297.
  10. Storm G., Crommelin D.J. Liposomes: quo vadis - // Pharmaceutical Science & Technology Today. 1998. V. 1. № 1. P. 19-31.
  11. Stefani A.-L. et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma // Journal of hepatology. 2005. V. 42. № 5. P. 728-735.
  12. Leal J.A., Feliciano A. and LLeonart M.E. Stem cell MicroRNAs in senescence and immortalization: novel players in cancer therapy // Medicinal Research Reviews. 2013. V. 33. № 1. P. 112-138.
  13. Davis T.A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin-s lymphoma: safety and efficacy of re-treatment // Journal of Clinical Oncology. 2000. V. 18. № 17. P. 3135-3143.
  14. Martinelli E. et al. Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy // Clinical & Experimental Immunology. 2009. V. 158. № 1. P. 1-9.
  15. Witzig T.E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin-s lymphoma // Journal of Clinical Oncology. 2002. V. 20. № 10. P. 2453-2463.
  16. Semenza G.L. Hypoxia-inducible factors in physiology and medicine // Cell. 2012. V. 148. № 3. P. 399-408.
  17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. 2011. V. 144. № 5. P. 646-674.